Targeted molecular therapy in peripheral T-cell lymphomas

Fernando Roncolato, Anna Gazzola, Pier Luigi Zinzani, Stefano A. Pileri, Pier Paolo Piccaluga

Research output: Contribution to journalArticle


Peripheral T-cell lymphomas (PTCLs) are rare neoplasms constituting a heterogeneous group of diseases. At present, available chemotherapy regimens that have improved outcomes in B-cell lymphomas appear to be less efficacious in the context of PTCLs and, thus, alternative strategies are warranted. In the last few years, based on the recent, deeper understanding of PTCL biology, several molecules and/or pathways have been proposed for targeted therapy in this setting, including surface antigens, tyrosine kinases, the NF-κB pathway, folate metabolism, histone modification and others. Of particular interest, histone deacetylase and proteasome inhibitors, as well as novel chemotherapeutic agents such as pralatrexate, have already demonstrated efficacy in PTCL therapy. In addition, a strong biological rationale and early clinical evidence supports the future study of tyrosine kinase inhibitors in this setting. In this article, the authors review the available literature on targeted therapy in PTCLs and also, based on their own experience, discuss potential opportunities in this intriguing area.

Original languageEnglish
Pages (from-to)551-562
Number of pages12
JournalExpert Review of Hematology
Issue number5
Publication statusPublished - Oct 2011


  • histone deacetylase inhibitors
  • monoclonal antibodies
  • peripheral T-cell lymphoma
  • proteasome inhibitors
  • targeted therapy
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Targeted molecular therapy in peripheral T-cell lymphomas'. Together they form a unique fingerprint.

  • Cite this

    Roncolato, F., Gazzola, A., Zinzani, P. L., Pileri, S. A., & Piccaluga, P. P. (2011). Targeted molecular therapy in peripheral T-cell lymphomas. Expert Review of Hematology, 4(5), 551-562.